Transform Deadly Cancer into a Chronic and Eventually Curable Disease
Transform Deadly Cancer into a Chronic and Eventually Curable Disease
Load image
Background image
About Us
About Us
Company Overview
We are a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types, with our multi-national R&D centers established in New Jersey and Hangzhou. With a strategic emphasis on oncology, we have identified and developed a robust pipeline of six drug candidates. We have assembled a management team and a scientific advisory board with industry leaders and influential scientists, who provide international and strategic guidance to our R&D, business development, and operational teams. In addition to building our own R&D capabilities, we continue to seek and secure partnerships with leading multi-national pharmaceutical companies such as Eisai Co., Ltd. or Eisai and Novartis Pharma AG or Novartis, to fully realize the potential of our pipeline programs. We are committed to becoming an innovative biotechnology company with global vision and strives to benefit patients worldwide. Our ultimate goal is to transform deadly cancer into a chronic and eventually curable disease.
Clinical Pipeline
Clinical Pipeline
R&D Platform
R&D Platform
Global Talent
Global Talent
View More
Background image Background image
Competitive Pipeline
We have identified and developed a robust pipeline of six drug candidates.Currently, our pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates.
View More
Background image Background image
Background image Background image Development Platform Development Platform
Research and Development
Platform
Led by an executive and core R&D team with industry leaders and influential scientists, who provide international and strategic guidance, we have built our unique immuno-oncology platforms. Our innovation team is well positioned to establish ourselves as a leading global presence in the oncology market.
View More
Media
View More